L-carnitine transport in kidney of normotensive, Wistar-Kyoto rats: Effect of chronic L-carnitine administration

Pharmaceutical Research

Volumn 20, Issue 8, 2003, Pages 1133-1140

  Gómez Amores, Lucía ^a   Mate, Alfonso ^a   Vázquez, Carmen M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Brush border membrane vesicles; Kidney; L carnitine transport; OCTN2; Wistar Kyoto rats

Indexed keywords

ACETYLCARNITINE; CARNITINE; CARRIER PROTEIN; GLUCOSE; PALMITOYLCARNITINE; PROPIONYLCARNITINE; PROTEIN OCTN2; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DIFFUSION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; ESTERIFICATION; FATTY ACID TRANSPORT; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EPITHELIUM; LONG TERM EXPOSURE; MICHAELIS CONSTANT; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RAT; REGRESSION ANALYSIS; SODIUM TRANSPORT; TRANSPORT KINETICS; URINARY EXCRETION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CARNITINE; CARRIER PROTEINS; DRUG ADMINISTRATION SCHEDULE; KIDNEY; MEMBRANE PROTEINS; MICROVILLI; ORGANIC CATION TRANSPORT PROTEINS; OSMOLAR CONCENTRATION; RATS; RATS, INBRED WKY; TIME FACTORS;

EID: 0042626565     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025080426970     Document Type: Article

References (35)

1. V. Tanphaichitr, D. W. Horne, and H. P. Broquist. Lysine, a precursor of carnitine in the rat. J. Biol. Chem. 246:6364-6366 (1971).
2. A. L. Carter, T. O. Abney, and D. F. Lapp. Biosynthesis and metabolism of carnitine. J. Child Neurol. 10:23-27 (1995).
3. E. P. Brass. Carnitine transport, In R. Ferrari, S. Dimauro, and G. Shewoord (eds.), L-Carnitine and its Role in Medicine: From Function to Therapy, Academic Press, New York, 1992, pp. 21-36.
4. K. Lahjouji, G. A. Mitchell, and I. A. Qureshi. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol. Gen. Metab. 73:287-297 (2001).
5. I. Tamai, R, Ohashi, J. I. Nezu, Y. Sai, D. Kobayashi, A. Oku, M. Shimane, and A. Tsuji. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J. Biol. Chem. 275:40064-40072 (2000).
6. B. Stieger, B. O'Neill, and S. Krähenbühl. Characterization of L-carnitine transport by rat kidney brush-border membrane vesicles. Biochem. J. 309:643-647 (1995).
7. W. Huang, S. N. Shaikh, M. E. Ganapathy, U. Hopfer, F. H. Leibach, A. Lee Carter, and V. Ganapathy. Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cells. Biochem. Pharmacol. 58:1361-1370 (1999).
8. K. Lahjouji, C. Malo, G. A. Mitchell, and I. A. Qureshi. L-carnitine transport in mouse renal and intestinal brush-border and basolateral membrane vesicles. Biochim. Biophys. Acta 1558:82-93 (2002).
9. +-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim. Biophys. Acta 1512:273-284 (2001).
10. W. R. Treem, C. A. Stanley, D. N. Finegold, D. E. Hale, and P. M. Coaters. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N. Engl. J. Med. 319:1331-1336 (1988).
11. M. Horiuchi, K. Kobayashi, S. Yamaguchi, N. Shimizu, T, Koizumi, H. Nikaido, J. Hayakawa, M. Kuwajima, and T. Saheki. Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport system. Biochim. Biophys. Acta 1226:25-30 (1994).
12. V. Tanphaichitr and P. Leelahagul. Carnitine metabolism and human carnitine deficiency. Nutrition 9:246-254 (1993).
13. T. C. Vary and J. R. Neely. A mechanism for reduced myocardial carnitine levels in diabetic animals. Am. J. Physiol. 242:H154-H158 (1982).
14. A. Gürlek, E. Tutar, E. Akcil, I. Dincer, C. Erol, P. A. Kocatürk, and D. Oral. The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur. J. Heart Fail. 2:189-193 (2000).
15. M. Fujiwana, T. Nakano, S. Tamoto, and Y. Yamada. Effect of L-carnitine in patients with ischemic heart disease. J. Cardiol. 21:493-504 (1991).
16. H. Rauchová, Z. Dobesová, Z. Drahota, J, Zicha, and J. Kunes. The effect of chronic l-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. Eur. J. Pharmacol. 342:235-239 (1998).
17. O. H. Wieland, T. Deufel, and I. Paetzke-Brunner. Free and esterified carnitine: Colorimetric method. In H. U. Bergmeyer HU (ed.), Methods in Enzymatic Analysis, Academic Press, New York, 1985, pp. 481-488.
18. R. S. Hare. Endogenous creatinine in serum and urine. Pro. Soc. Exp. Biol. Med. 74:148-152 (1950).
19. A. Mate, M. A. de la Hermosa, A. Barfull, J. M. Planas, and C. M. Vázquez. Characterization of D-fructose transport by rat kidney brush-border membrane vesicles: changes in hypertensive rats. Cell. Mol. Life Sci. 58:1-7 (2001).
20. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).
21. J. P. Bretaudiere, A. Vassault, L. Amsellem, M. L. Pourc, H. Thieu-Phung, and M. Bailly. Criteria for establishing a standardized method for determining alkaline phosphatase activity in human serum. Clin. Chem. 23:2263-2274 (1977).
22. B. Colas and S. Maroux. Simultaneous isolation of brush border and basolateral membrane from rabbit enterocytes. Biochim. Biophys. Acta 600:406-420 (1980).
23. R. J. Pennington. Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem. J. 80:649-652 (1961).
24. D. R. Absolom. Basic methods for the study of phagocytosis. Methods EnzymoL 132:95-180 (1986).
25. A. G. Engel, C. J. Rebouche, D. M. Wilson, A. M. Glasgow, C. A. Romshe, and R. P. Cruse. Primary systemic carnitine deficiency: II. Renal handling of carnitine. Neurology 31:819-825 (1981).
26. C. J. Rebouche and D. L. Mack. Sodium gradient-stimulated transport of l-carnitine into renal brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch. Biochem. Biophys. 235:393-402 (1984).
27. M. Spaniol, H. Brooks, L. Auer, A. Zimmermann, M. Solioz, B. Stieger, and S. Krähenbühl. Development and characterization of an animal model of carnitine deficiency. Eur. J. Biochem. 268:1876-1887 (2001).
28. P. G. Welling, J. H. Thomsen, A. L. Shug, and F. L. Tse. Pharmacokinetics of L-carnitine in man following intravenous infusion of dl-carnitine. Int. J. Clin. Pharmacol. Biopharm. 17:56-60 (1979).
29. T. Kalaiselvi and C. Panneerselvam. Effect of L-carnitine on the status of lipid peroxidation and antioxidants in aging rats. J. Nutr. Biochem. 9:575-581 (1998).
30. S. Berardi, B. Stieger, B. Hagenbuch, E. Carafoli, and S. Krähenbühl. Characterization of L-carnitine transport into rat skeletal muscle plasma membrane vesicles. Eur. J. Biochem. 267:1985-1994 (2000).
31. I. Tamai, R. Ohashi, J. I. Nezu, H. Yabuuchi, A. Oku, M. Shimane, Y. Sai, and A. Tsuji. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 273:20376-20383 (1998).
32. F. Scaglia, Y. Wang, and N. Longo. Functional characterization of the carnitine transporter defective in primary carnitine deficiency. Arch. Biochem. Biophys. 364:99-106 (1999).
33. +-dependent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778-784 (1999).
34. Y. Wang, T. A. Meadows, and N. Longo. Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency. J. Biol. Chem. 275:20782-20786 (2000).
35. +-carnitine cotransporter hOCTN2. Am. J. Physiol. 279:F584-F591 (2000).